Browsing Tag
Mabwell
4 posts
Mabwell begins first-in-class Phase II trial of IL-11 antibody 9MW3811 for scarring in China
Mabwell dosed the first patient in its Phase II trial for IL-11 antibody 9MW3811, targeting pathological scarring. Find out what makes this a global first.
Mabwell’s adalimumab biosimilar wins BPOM nod: Is Southeast Asia becoming the next battleground for biosimilars?
Mabwell’s adalimumab biosimilar wins approval in Indonesia. Find out what this means for Southeast Asia’s biologics market and Mabwell’s global ambitions.
Mabwell’s anti-ST2 antibody enters U.S. trials: Can 9MW1911 reshape immunotherapy for COPD?
Mabwell’s anti-ST2 antibody 9MW1911 enters U.S. trials after strong COPD data in China. Find out what this could mean for immunotherapy's future in COPD.
FDA clears Mabwell’s next-gen ADC 7MW4911: What’s at stake in the global GI oncology race?
Mabwell secures FDA IND for CDH17-targeting ADC 7MW4911, marking a major step in GI cancer therapy. Find out how this could reshape advanced oncology care.